Form 8-K - Current report:
SEC Accession No. 0000926617-23-000011
Filing Date
2023-02-07
Accepted
2023-02-07 16:00:28
Documents
13
Period of Report
2023-02-06
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K awh-20230206x8k.htm   iXBRL 8-K 68596
2 EX-3.1 awh-20230206xex3_1.htm EX-3.1 12709
  Complete submission text file 0000926617-23-000011.txt   211357

Data Files

Seq Description Document Type Size
3 EX-101.SCH awh-20230206.xsd EX-101.SCH 2548
4 EX-101.LAB awh-20230206_lab.xml EX-101.LAB 16150
5 EX-101.PRE awh-20230206_pre.xml EX-101.PRE 11611
7 EXTRACTED XBRL INSTANCE DOCUMENT awh-20230206x8k_htm.xml XML 5150
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 23594988
SIC: 2835 In Vitro & In Vivo Diagnostic Substances